The Earlier the Better in Lung Cancer: Multispecialty Guidance on Screening, Diagnosis and Management of Resectable NSCLC

Chair, Prof. Sanjay Popat, FRCP, PhD, and presenters Prof. Joachim G. Aerts, MD, PhD, and Prof. Solange Peters, MD, PhD, discuss NSCLC in this CME activity titled “The Earlier the Better in Lung Cancer: Multispecialty Guidance on Screening, Diagnosis and Management of Resectable NSCLC.” For the full presentation, downloadable Practice Aids, and complete CME information, and to apply for credit, please visit us at https://bit.ly/3Goyt9D. CME credit will be available until October 20, 2026.

1. The Earlier the Better

Multispecialty Guidance on Screening, Diagnosis, and
Management of Resectable NSCLC

Prof. Sanjay Popat, FRCP, PhD Prof. Joachim G. Aerts, MD, PhD
Consultant Medical Oncologist Head of Pulmonary Medicine
Royal Marsden Hospital : Erasmus MC University Hospital
Professor of Thoracic Oncology è Rotterdam, the Netherlands

The Institute of Cancer Research
London, England, United Kingdom

Prof. Solange Peters, MD, PhD
Chair and Professor, Medical Oncology
Full Professor

University Hospital of Lausanne
Lausanne, Switzerland

Go online to access full CME information, including faculty disclosures.

Copyright © 2000-2025, PeerView

2. Our Goals for Today

Augment your knowledge of current recommendations for
and experiences with lung cancer screening across Europe
and the UK

Equip you with skills to evaluate, diagnose, and develop
appropriate treatment plans for patients with stage I-III
NSCLC

Enhance your ability to optimally integrate immunotherapy-
based strategies into treatment plans of patients with
resectable NSCLC

Copyright © 2000-2025, PeerView

3. Identifying Risk Factors and Interpreting
Guidelines for the Screening of Lung
Cancer Across Europe and UK

Copyright © 2000-2025, PeerView

4. PeerView.com/JYH827 Copyright

ung Cancer Statistics in European Count!

Ss

Stage at Diagnosis
Lung Cancer

Stage ll Stage Ill

on ~70% at advanced stage

92%

67% 5-year survival rate

New cases in 35-40%
470,039 Europe (2018)
aN
O, Of all deaths from
~20 % cancer (2021)

1 eo Canal Amen ED LEE DB AAC ED da POTRO NOAA 3 Tre Lang Cata Pale) Netw Faw
ies Lennon cp ung cece sten eamung Fominpiemenlaln.d PeerView

> 2000-2025, Peel

5. Lung Cancer Screening (LCS): Advancing Early Detection!

16% 10% 17% 57%

Diagnosed
outside of a
screening

programme

Stage! Stage ll Stage Ill

Low-dose computed
tomography

77% Th 9% 7%

A ¿e
so?
Diagnosed of

ina
cena stag Stage I Stage 11 Stage IVI 20%
programme 0

1, The Lung Cancer Poly Network. ps ww Jungcancerpoheyetwork.com/appupladsLung-<ancer-<reering-iearing-rom-mpiementten.pa.2. e Nateral Do 6 View
Lung Sereening Trial Research Team. N Eng! J Mod. 2011;365:395-409. 3. de Koning HJ et al. N Eng! J Med. 2020.382-503-513. eervie

PeerView.com/JYH827 Copyright © 2000-2025, Peerview

6. here Do We Stand With LCS: Recommendations

European Council updated its recommendation to include lung

— cancer screening (2022)':
——— + Low-dose computed tomography

— + Astepwise approach
— + Feasibility and effectiveness
= + High-risk individual: heavy smokers and ex-smokers who used to smoke

heavily, and other high-risk profiles

UK National Screening Committee's (UK NSC) announced

targeted lung cancer screening (2022)?:

+ Low-dose computed tomography

+ High-risk individual: people aged 55 to 74

+ Integrate smoking cessation service provision

+ Targeted Lung Health Checks (TLHC) programme provides a feasible and
effective starting point for implementation in England

Committee

1 tgs auopaterops cute ng oureropean way ee cancer seeing i
isa ei PeerView

PeerView.com/JYH827 Copyright © 2000-2025, Peerview

7. Implementation’?

here Do We Stand Wit

@ERS z
ES] deat

In Europe, to date, there are no unified
guidelines on LCS provided by
professional or governmental organisations.
However, in November 2022, following the
recommendation of the European Council
regarding LCS, two European Respiratory
Society task forces were formed to provide
a technical standard for a high-quality LCS
programme and a management protocol for
incidental LCS findings.

PeerView

4. Baldwin D tal. Eur Respir J. 2023.51:2300128. 2. ODowd EL etal Eur J Cardiothorac Surg. 2028/84 ezad302.

PeerView.com/JYH827 Copyright © 2000-2025, Peerview

8. ere Do We Stand Wit!

@ERS
SR sd

In Europe, to date, there are no unified
guidelines on LCS provided by
professional or governmental organisations.
However, in November 2022, following the
recommendation of the European Council
regarding LCS, two European Respiratory
Society task forces were formed to provide
a technical standard for a high-quality LCS
programme and a management protocol for
incidental LCS findings.

Implementation

LACE

SOLACE aims at developing, testing and
disseminating tools to help overcome
identified bottlenecks and specifically address
the health inequalities in different European
countries. It will provide a toolbox for
individualised approaches for lung cancer
screening on a national or regional level.
Austria, Belgium, Croatia, Czechia, Estonia,
France, Germany, Greece, Hungary, Ireland, Italy,
Netherlands, Poland, Romania, Spain

Downloadable resources and information
for healthcare practitioner?

PeerView

4. Baldwin D tal. Eur Respir J. 2023.51:2200128. 2, ODowd EL el al. Eur J Cordothrac Surg. 2028/64e2a4302. 3. hpsileuropeaniungorp/solace

PeerView.com/JYH827 Copyright © 2000-2025, PeerView

9. Lessons From Lung Cancer Screening Implementation‘

Tailor eligibility criteria Develop targeted
for screening to reach outreach to address
those at highest risk potential barriers to

of lung cancer participation in LCS

+ Adapt eligibility criteria + Understand barriers to

+ Optimise risk predication screening attendance
models + Ensure screening

+ Optimise use of programme is.
biomarkers geographically appropriate

+ Engage high-risk individuals

‘Amplify the impact of
LCS by integrating into
other public health
initiatives

Integrate smoking cessation
Combine with other
screening programmes

Try lo detect other diseases

Ensure the full
integration of LCS into
health systems

Ensure adaptability to local
‘context and health system
Invest in multidisciplinary
care

Take a comprehensive
approach to planning

1. The Lung Cancer Poly Network. hips: www lungeancerpoieynetwork convappluploadsiLung-cancer screening learning fom implementation pa

PeerView.com/JYH827

O

US: adjusting guidelines to expand eligibility and improve equity of screening

China: addressing increased risk for lung cancer in tin miners due to occupational exposure

PeerView

Copyright © 2000-2025, PeerView

10. Lung cancer in individuals who have
never smoked is estimated to be the
fifth most common cause of cancer-
E a related deaths worldwide in 2023,
history preferentially occurring in women
Tobacco Environmental and Asian populations.

(smoking)

What does this mean for LCS:
Eligibility criteria for screening
should be tailored to local contexts
and adapted where appropriate to
ensure greater equity in recruitment

Tuberculosis Pneumonia for lung cancer screening
programmes.
1. Te Lung Cancer Pole Network. ps vir lungeancepotemetvork com app/upbadsLung-cance-sreening earring trom implementa pat PeerView

2 Lapices J eal Ht Ro Cin Oncol 2024 21.121148. 2. hips european or/slacel202507/9onrr<kgle faring cancer screening ect

PeerView.com/JYH827 Copyright © 2000-2025, PeerView

11. Lessons From Lung Cancer Screening Implementation‘

Tailor eligibility criteria
for screening to reach
those at highest risk
of lung cancer

+ Adapt eligibility criteria

+ Optimise risk predication
models

+ Optimise use of
biomarkers

Develop targeted
outreach to address
potential barriers to
participation in LCS

+ Understand barriers to
screening attendance

+ Ensure screening
programme is.
geographically appropriate

+ Engage high-risk individuals

Amplify the impact of
LCS by integrating into
other public health
initiatives

Integrate smoking cessation
Combine with other
screening programmes

+ Try to detect other diseases

Ensure the full
integration of LCS into
health systems

Ensure adaptability to local
context and health system
Invest in multidisciplinary
care

Take a comprehensive
approach to planning

1. The Lung Cancer Pole Network ts ww lungeancerpoicynetwark conVapp/uploads/Lung cancer screening learning fem-implementaion pat

PeerView.com/JYH827

UK: overcoming informational barriers and stigma by presenting screening as a lung health check

New Zealand: learning how to engage marginalized commu

programmes

s from other cancer screening

PeerView

Copyright © 2000-2025, PeerView

12. Lessons From Lung Cancer Screening Implementation!

Tailor eligibility criteria
for screening to reach
those at highest risk
of lung cancer

+ Adapt eligibility criteria

+ Optimise risk prédication
models

+ Optimise use of
biomarkers

Develop targeted
outreach to address
potential barriers to
participation in LCS

+ Understand barriers to
screening attendance

+ Ensure screening
programme is
geographically appropriate

+ Engage high-risk individuals

Amplify the impact of
LCS by integrating into
other public health
initiatives

Integrate smoking cessation
Combine with other
screening programmes

+ Try to detect other diseases

Ensure the full
integration of LCS into
health systems

Ensure adaptability to local
context and health system
Invest in multidisciplinary
care

Take a comprehensive
approach to planning

1. The Lung Cancer Poly Network. hllps www lungeancerpoieynetwork convappluploadsiLung-cancer screening learning fom implementation par.

PeerView.com/JYH827

France: detecting other diseases as part of lung cancer screening

Sweden: engaging women in lung cancer screening who are

programmes

volved in other cancer screening

PeerView

Copyright © 2000-2025, PeerView

13. Lessons From Lung Cancer Screening Implementation!

Tailor eligibility criteria Develop targeted
for screening to reach outreach to address
those at highest risk potential barriers to

of lung cancer participation in LCS

+ Adapt eligibiity criteria + Understand barriers to

+ Optimise risk predication screening attendance
models + Ensure screening

+ Optimise use of programme is
biomarkers geographically appropriate

+ Engage high-risk individuals

Amplify the impact of
LCS by integrating into
other public health
initiatives

Integrate smoking cessation
Combine with other
screening programmes

Try lo detect other diseases

Ensure the full
integration of LCS into
health systems

Ensure adaptability to local
context and health system
Invest in multidisciplinary
care

Take a comprehensive
approach to planning

1. The Lung Cancer Pole Network. hllps www lungeancerpoieynetwork convappluploadsiLung-cancer screening learning fom implementation par.

PeerView.com/JYH827

Croatia: accelerating waiting lists for specialist care to avoid bottlenecks in the care pathway

US: creating screening centres of excellence

PeerView

Copyright © 2000-2025, PeerView

14. Faculty Discussion & Perspectives:
The Implementation Challenges in LCS

025, PeerView

15. Let’s Consider a Case

59-year-old male, 20 pack-year smoking history, invited for a lung health check at a CT mobile unit
5/2023: imaging revealed 7-mm LUL nodule, GGO without a solid component, put on surveillance CT

1/2024: CT shows nodule slightly increased in size, ground glass area had started to solidify, no
adenopathy

PET scan: modest FDG avidity
2/2024: LUL nodule now 9 mm

Would your approach differ in any way?

PeerView

PeerView.com/JYH827 Copyright © 2000-2025, Peerview

16. A Step-Wise Approach to Diagnosis,
Staging, and Clinical Work-Up of
Early NSCLC

2000-2025, PeerView

17. ESMO Recommendation for Diagno:

and Staging of Early NSCLC’

General

Laboratory

Cardiopulmonary
function

Biopsy

Molecular testing

Mandatory

Medical history, physical examination, comorbidity,
and PS

CT thorax and upper abdomen, PET-CT, MRI brain
Blood cell counts, renal function, liver enzymes

FVC, FEV1, DLCO, ECG. If indicated: CPET
Bronchoscopy, EBUS/EUS mediastinal nodes,
CT-guided biopsy

EGFR mutation status, PD-L1 expression (for
unresectable NSCLC)

41. Remon J ela. Ann Oncol. 2021.32-1837-1842.

PeerView.com/JYH827

‘Sean tho GR code to access
‘the newly released 2025,
ESMO guidelines for arty
and locali advanced NSCLC

X-ray thorax, bone scintigraphy,
contrast-enhanced CT brain

Bone parameters
Ejection fraction, CAG
Mediastinoscopy

ALK fusion status

PeerView

Copyright © 2000-2025, PeerView

18. Algorithm fo coregional Lymph Node Staging!

Mediastinal LNs
positive

Tissue confirmation:
EBUSIEUS

jastinal LNs
on EBUS/EUS

Mediastinal LNs
positive

Mullimodaliy treatment

PeerView

1. Remon Jet al. Ann Oncol. 2021:32:1837-1042,

PeerView.com/JYH827 Copyright © 2000-2025, PeerView

19. Biomarker Testing in Early-Stage NSCLC: Why it Matters!

Early biomarker testing can guide Pathologist-Initiated Reflex Testing for Biomarkers

appropriate treatment selection and
planning in early-stage NSCLC

+ Guides use of targeted therapies in the scleral ENG D

curative setting tions if using NC

+ Informs immunotherapy eligibility

+ Avoids missed opportunities due to
postoperative limitations (eg, limited tumour
tissue)

+ Optimise sequencing, avoids harmful ñ
treatment overlaps (eg, EGFR-TKIs after Beat Adjuvant
immunotherapy — higher pneumonitis risk) tment

jon and
ali

early-stage treatment
NSCL discussion

+ Support clinical trial enrollment

1. Herbst Ret al. ASCO 2023, Abstract LBA3. 2. Tsubol M et al. N Eng! J Med. 2023:386:137-147. 3, Solomon B etal. ESMO 2023. Abstract LBA2, PeerVi
4. Schoenfeld AJ et al. Ann Oncol. 2019;30:839-844. 5. Gosney JR et al. ESMO Open. 2023:8:101587. eerview

PeerView.com/JYH827 Copyright © 2000-2025, PeerView

20. The Importance of Early Involvement of A Multidisciplinary Team

Multidisciplinary Approach From Screening to Palliative Care

Oncologist

Radiologists,
nuclear medicine)
specialists

Lung function testing as per set standards 10 | Lung function Pathologist sation of tissue proc
ensure a representative measurement technician rate diagnosis and

1. Adapted rom Hardaveña © et al. Breathe (Shof.2024:20 240048.

PeerView

PeerView.com/JYH827 Copyright © 2000-2025, PeerView

21. N2 sur N2 wvasive

13 sae

Potentially

13 sareure ie

13m

en

TA careers
Ta,

nan

1.Hou etl, Lng Cancer 202519910806. PeerView

PeerView.com/JYH827 Copyrigh

22. Tumour

+ Operability: patient wishes, performance and risk tolerance (highly variable)

+ Surgeon experience and risk tolerance (highly variable)

+ Baseline physiology to achieve accurate risk assessment (eg, PFTs, VO2 max,
6-min walk test, quantitative V/Q, ECOG, nutritional status, overall exercise
tolerance, lifestyle, comorbidities)

+ Predicted postoperative functional reserve/QOL based on extent of pulmonary
resection required for RO

+ Feasibility of RO at baseline and based on expected response (guided by
biomarker profile, functional reserve, type of neoadjuvant regimen employed,
surgical experience)

+ How does risk/benefit profile of a surgical course compare with risk/benefit profiles
of alternatives? Patient preference?

PeerView

PeerView.com/JYH827 Copyright © 2000-2025, PeerView

23. , Staging, and Clinical Work-Up

Referral to specialist Oncologist

Radiologist

‘Surgeon MoT
Oncologist Radiologist Pulmonologist "y

Radiologists puimonologist Se Surgeon Le Bs Sa

2 22 22 a £8
y MA

& Reflex testing
oo
Pathologist

PeerView

PeerView.com/JYH827 Copyright © 2000-2025, Peerview

24. nue Our Case

a
+ 59-year-old male, 20 pack-year smoking history, invited for a lung health check at a CT mobile unit
+ 5/2023: imaging revealed 7-mm LUL nodule, GGO without a solid component, put on surveillance CT
+ 1/2024: CT shows nodule slightly increased in size, ground glass area had started to solidify, no
adenopathy
+ PET scan: modest FDG avidity
+ 2/2024: LUL nodule now 9 mm
+ PET scan shows 1.0 LUL nodule (SUV 2.4), enlarged L paratracheal node (SUV 8.5), no distant disease
ce
erView

Copyright © 2000-2025, PeerView

25. Let’s Continue Our Case

EBUS performed; station 4L was enlarged and sampled, and there were no other enlarged nodes but
contralateral R2 and R4 nodes were also biopsied

Level 4 (2/2 LN +) c/w lung adenocarcinoma, TTF-1 positive
Contralateral lymph nodes negative

NGS shows no targetable alterations and PD-L1 20%

Brain MRI negative

Staged as IIIA (T1bN2)

PeerView

PeerView.com/JYH827 Copyright O 2000-2025, Peerview

26. Faculty Discussion & Perspectives:
Diagnosing & Staging Early NSCLC

05

000

1000-2025, PeerView

27. Aligning Options to the Individual
Selection of Optimal Approaches in
Resectable NSCLC

Copyright © 2000-2025, PeerView

28. Curative Therapy for Locally Advanced NSC

The clinical goals of early-stage therapeutic management

For local-regional
control

Surgery .
Es Radiation therapy

To reduce risk u
of distant relapse
Chemotherapy

Targeted therapy
Immunotherapy

Systemic therapy

PeerView

PeerView.com/JYH827 Copyright © 2000-2025, Peerview

29. Treatment Landscape for Early-Stage and Locally Adv

Resectable NSCLC’

Current treatment

Neoadjuvant
option

treatment

Potential future
treatment option [CheckMate -816:]
10 +CT
25%

No AGAS Not IO-sensitive

ge 10-sensitive AGAS
Wade AGAs (eg, EGFR, ALK)
50%
Resectable Adjuvant treatment

IMpower010*
PEARLS/KEYNOTE-0912
tin

For tumours with!

ADAURA*
ALINA®

Not IO-sensitive
No AGAs or

AGAs
10-sensitive AGAs NoAGAs
10-sensitive (eg, EGFR, ALK)
4500 regimen. Des

4. Cascone T et al, WLC 2024.

PeerView.com/JYH827

Perioperative
treatment

NoAGAS Not IO-sensitive
10-sensitive AGAs
AGAs (eg, EGFR, ALK)

Surgery

NoAGAs Not IO-sensitive
10-sensitive AGAS
AGAS (eg, EGFR, ALK)
KEYNOTE-6719
‘AEGEAN?
CheckMate -77T
NEOTORCH
RATIONALE-315

PeerView

Copyright O 2000-2025, Peerview

30. Incorporating Immunotherapy Into Treatment Plans in
Resectable NSCLC

Select appropriate patients

Understand the evidence

Determine sequence of therapies

00€

Monitor and manage adverse events

|

PeerView

PeerView.com/JYH827 Copyright © 2000-2025, PeerView

31. Patient Selection Considerations

Staging

Physiologic Evaluation
Biomarker testing

CT
PET PFTS
EBUS/med Cardiac evaluation EGFR

Brain MRI Exercise testing ALK
NGS for other alterations

PD-L1

Frailty assessment

PeerView

PeerView.com/JYH827 Copyright © 2000-2025, Peerview

32. Understand the Evidenc

With Neoadjuvant ICI

PCR Rate (ypTONO) per BIPR
(Resected + non-resected population)

(Os rato: 13.94 (99% CI, 340-5575)
Dr

2,»
# an
i HE
3 220
E dä»

Po

ee ee ee ee NET ETE TETERA
Tae, mo a Timo, mo

A

PeerView

1. Forde PM et. N Engl JMod.2022.388:1973-1985. 2 Spier JD et al. ASCO 2024, 3. Forde PM el al. ASCO 2025. Abstract LBABODO.

PeerView.com/JYH827 Copyright © 2000-2025, PeerView

33. Perioperative Immunotherapy?

AEGEAN: Perioperative DURVA Improved EFS, With a KEYNOTE-671 1A2: Perioperative PEMBRO Improved
Favorable OS Trend os EFS and OS

A AS ERRE
Er di
Y. Heymach JV. WLC 2024. 2. Spicer JD e al Lance 2024.404:p1240-1252. 3. Cascone Teal. ASCO 2035. Abarat LBABDIO. PeerView

PeerView.com/JYH827 Copyright © 2000-2025, Peerview

34. Underst the Evidence: Improvements in Efficacy Wi

Adjuvant ICI (IMpower010 and

IMpower010: DFS and OS in PD-L1 TC 21%
stage II-IIIA population; >60 mo follow-up

CCTG BR.31: DFS in PD-L1 225% EGFR-/ALK-

ba Paar md

DFS Survival Probability

1. Wakelee HA et al ASCO 2021. Abstract 8600. 2. Fei E etal. Lancet. 2021:986:1944-1957. 3. Wakelee HA etal, ASCO 2024. 4. Goss G etal ESMO 2024, PeerVi
5. Paz-Ares L et al. ESMO Plenary 2022. 6. O'Brien MER et al. ASCO 2022. 7. O'Brien MER. Lancet Oncol. 2022:23:1274-1286. eerview

PeerView.com/JYH827 Copyright © 2000-2025, PeerView

35. Treatment Selection Considerations

Neoadjuvant Adjuvan Perioperative
( Earyeradication |] eradication DS) is standard of care Allows for [es reses erat] amount
of micrometastatic disease for resectable AA) 18 and Il disease of AAA therapy
Healthier patients with improved Early eradication
tolerance of drug toxicity NOCHE EIGER of micrometastatic disease
Improved adherence Tumour biomarkers can guide ‘Opportunity for pre- and post-treatment
and higher drug exposure therapeutic decisions tissue to adjust treatment
E)
‘Opportunity for pre- and post-treatment E 7 h Tumour biomarkers can guide
tissue to adjust treatment EE therapeutic decisions

Neoadjuvant is the standard of care

for resectable stage Ill disease) resulting in missed opportunity activation of broader and more

for curative surgery diverse immune response

No risk of disease progression Presence of whole tumour allows

Presence of whole tumour allows
activation of broader and more diverse

immune response PeerView

PeerView.com/JYH827 Copyright O 2000-2025, Peerview

36. How to Select Best Strategy?

Anatomic Extent of the Disease Multidisciplinary Team
Staging O ms
+ T size, invasion Medical

Patient Preference
Histology/Biomarker

Histologic type, grading

Driver gene... EGFR, ALK, others _

PD-L1 y

ctDNA = ln

Pharmacist Nurse

PeerView.com/JYH827

+ N: multiple, bulky, extranodal? oncologist
+ M: oligo? a
i a i
Thoracic

Planned op procedures surgeon ET tor
+ Pneumonectomy * x ‘oncologist
+ Angio-/bronchoplasty

x x

2]
+ +

CS

|

Physio
therapist

Patient Condition
General
- PS
os
+ Organ reserve

Surgical tolerability
+ Cardiopulmonary function

Immunotherapy tolerability
+ ILD
+ AID

Targeted drug tolerability
+ ILD
+ QT prolongation

Radiation tolerability

[XA

PeerView

Copyright © 2000-2025, PeerView

37. Returning to Our Case

+ 59-year-old male, 20 pack-year smoking history, invited for a lung health check at a CT mobile unit

+ 5/2023: imaging revealed 7-mm LUL nodule, GGO without a solid component, put on surveillance CT

+ 1/2024: CT shows nodule slightly increased in size, ground glass area had started to solidify, no
adenopathy

+ PET scan: modest FDG avidity
+ 2/2024: LUL nodule now 9 mm
PET scan shows 1.0 LUL nodule (SUV 2.4) enlarged L paratracheal node (SUV 8.5), no distant disease

erView

con 327 Copyright © 2000-2025, PeerView

38. Returning to Our Case (Cont'd)

EBUS performed; station 4L was enlarged and sampled, and there were no other enlarged nodes but
contralateral R2 and R4 nodes were also biopsied

Level 4 (2/2 LN +) c/w lung adenocarcinoma, TTF-1 positive
Contralateral lymph nodes negative

NGS shows no targetable alterations and PD-L1 20%

Brain MRI negative

Staged as IIIA (T1bN2)

PeerView

PeerView.com/JYH827 Copyright © 2000-2025, Peerview

39. Faculty Discussion & Perspectives:
Treatment Options & Considerations for rNSLSC

Copyright © 2000-2025, PeerView

40. Patient starts neoadjuvant chemotherapy + immunotherapy

After 4 cycles, decrease observed in paraaortic/pretracheal adenopathy and mass was mostly stable

rView

Copyright © 2000-2025, PeerView

41. Our Case Continues

Patient undergoes uniportal L upper lobectomy and thoracic lymphadenectomy
Surgeon notes no significant scarring or fibrosis and positive paraaortic LN

Pathology shows invasive adenocarcinoma, 0.8 cm tumour size, +LVI, negative margins, PLO, 3/18 LN
positive (1 level 3, 2 hilar; no nodal capsular invasion), and treatment effect >20% residual tumour

Final stage: ypT1aN2

PeerView

PeerView.com/JYH827 Copyright © 2000-2025, Peerview

42. Faculty Discussion & Perspectives:
Treatment Options & Considerations for rNSLSC

2025, PeerView

43. Safety Considerations Associated With Immunotherapies**

== fade 3-4 Discontinuation irAEs: Become Aware and Stay Vigilant
is TRAES due to TRAES
Neoadjuvant
Necadwvant CheckMate 816 24% 33.5% 102%
Agar Mpowero10 ex 11% 19%
Weinen PEMRSNENOTE zu ‘om sin
KeyNoTes71 vorn 40% 120%
et AEGEAN 627 424% 120%
CheckMate 777 sex 325% 193%

Neon
Ex Create 18 = Rash, peunonis|
Mao 62% (8%) E
Adnan reinen! PEARLSIKEYNOTE apy 193 > PIPE, pertrain.
ES ‘neumont, hepa, cle
253% Hypatyroiim, Mpertyracem.
Eee (5.8%) pneumonitis:
Peroperive zum
en non 2 E
CheckMate 777. _Hypothyroidisnvthyroiditis,

pneumonitis sash, hypertnyroiciem

1. Forde PM et al. N Engl J Med. 2022:386:1973-1985. 2. Felip E et al. Lancet. 2021-396; 1344-1357. 3. O'Brien M, et al. Lancet Oncol. 2022:23:1274-1286. 4. Wakelee P Vi Y
AL Engl Med 2023.90 01-20, 5. Heymach tal. N Engl Jd. 2023350 1872 1884. 8. Cascen Tet lM Engl Hed 2024 200-1750 175. eerView

PeerView.com/JYH827 Copyright © 2000-2025, PeerView

44. AE Management

ESMO Guidelines: Management of IR-ILD'

irAEs: General Management Recommendations a+ nr nt are
came | | sf one Urn Ts Ca eS CRP,
eg pre er peace
Managed in Generally requires le ataca ces
utpallenicommunty setting, hospital admission EE
+ > > [mare] | romeros werte creme
pi | [ean wena ya tnd este aa,
= Grameen etree [roma un vu ern
a ess ME
BE mene spent Basen an
85 Oral steroids — Intravenous steroids —> ans Ts redes TUCO
ge asa =>
SE Step atan — JON TN —
E ee PEA
ñ ==
HS
É uo ran cera nara x wanna : ON
[m Moderate Very seee “cnn eno
Increasing Grade of irAE Dee
ee

4. Haanen Jt al. An Oncol 2022,9:1217-1238 PeerView

PeerView.com/JYH827 Copyright © 2000-2025, PeerView

45. Faculty Discussion & Perspectives:
Treatment Options & Considerations for rNSLSC

46. Lung Cancer Screening Saves Lives: Early detection through national or regional
LCS programmes (such as those offered by NHS in the UK or similar programmes in
other European countries) helps identify NSCLC at earlier, more treatable stages.

Multidisciplinary Collaboration: A multidisciplinary approach involving oncologists,
thoracic surgeons, radiologists, pathologists, and pulmonologists is critical for
determining the optimal treatment approach.

Biomarker Testing: PD-L1 testing and molecular profiling are crucial to guide therapy
and ensure that patients receive the most effective treatment based on tumour
characteristics. This aligns with the European guidelines for managing NSCLC.

Immunotherapy Benefits: Evidence from clinical trials supports the use of
immunotherapy to improve outcomes in resectable NSCLC.

PeerView

PeerView.com/JYH827 Copyright © 2000-2025, PeerView